Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | CH5N3.ClH |
| Molecular Weight | 95.531 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC(N)=N
InChI
InChIKey=PJJJBBJSCAKJQF-UHFFFAOYSA-N
InChI=1S/CH5N3.ClH/c2-1(3)4;/h(H5,2,3,4);1H
Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.
Originator
Sources: https://d-nb.info/1059797615/34
Curator's Comment: Original article: A. Strecker, Liebigs Ann. Chem. 1861, 118, 151-177.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2362996 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | GUANIDINE HYDROCHLORIDE Approved UseGuanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis. Launch Date1939 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The picornavirus replication inhibitors HBB and guanidine in the echovirus-9 system: the significance of viral protein 2C. | 2000 Apr |
|
| The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty. | 2001 |
|
| Dihydrofolate reductase from Thermotoga maritima. | 2001 |
|
| Strain-specified relative conformational stability of the scrapie prion protein. | 2001 Apr |
|
| The structure of human mitochondrial branched-chain aminotransferase. | 2001 Apr |
|
| Human recombinant interferon-inducible protein-10: intact disulfide bridges are not required for inhibition of hematopoietic progenitors and chemotaxis of T lymphocytes and monocytes. | 2001 Feb |
|
| [Discovery of cis-preference of aromatic N-methylamides and its application to molecular constructions]. | 2001 Feb |
|
| Specific neosaxitoxin interactions with the Na+ channel outer vestibule determined by mutant cycle analysis. | 2001 Feb |
|
| Spontaneous and flow-induced Ca2+ transients in retracted regions in endothelial cells. | 2001 Feb 16 |
|
| Molecular specificities of antibodies against ovine and murine recombinant prion proteins. | 2001 Feb 16 |
|
| Cellular responses of NG108-15 and SK-N-MC lines to sweet and bitter tastants as measured by extracellular acidification rates. | 2001 Jan 1 |
|
| Folding-unfolding of goat alpha-lactalbumin studied by stopped-flow circular dichroism and molecular dynamics simulations. | 2001 Jan 1 |
|
| The influence of ATP on the association and unfolding of the tyrosine repressor ligand response domain of Haemophilus influenzae. | 2001 Jan 12 |
|
| Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains. | 2001 Jan 12 |
|
| The PD...(D/E)XK motif in restriction enzymes: a link between function and conformation. | 2001 Jan 16 |
|
| Analysis of the Desulfovibrio gigas transcriptional unit containing rubredoxin (rd) and rubredoxin-oxygen oxidoreductase (roo) genes and upstream ORFs. | 2001 Jan 19 |
|
| Engineering conformational flexibility in the lactose permease of Escherichia coli: use of glycine-scanning mutagenesis to rescue mutant Glu325-->Asp. | 2001 Jan 23 |
|
| [Y97V substitution in the horse cytochrome c causes accumulation of the equilibrium intermediate]. | 2001 Jan-Feb |
|
| Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride. | 2001 Mar |
|
| Dramatic stabilization of an SH3 domain by a single substitution: roles of the folded and unfolded states. | 2001 Mar 30 |
|
| The structure of denatured alpha-lactalbumin elucidated by the technique of disulfide scrambling: fractionation of conformational isomers of alpha-lactalbumin. | 2001 Mar 30 |
|
| Osmolytes protect mitochondrial F(0)F(1)-ATPase complex against pressure inactivation. | 2001 Mar 9 |
|
| The dimerization of folded monomers of ribulose 1,5-bisphosphate carboxylase/oxygenase. | 2001 Mar 9 |
|
| Replacement of thrombin residue G184 with Lys or Arg fails to mimic Na+ binding. | 2001 May 15 |
Sample Use Guides
Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.
Route of Administration:
Oral
Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C45678
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
CONCEPT | Industrial Aid | ||
|
C47551
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
755884
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
50676
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | RxNorm | ||
|
50-01-1
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
5742
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
SUB14035MIG
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
1302134
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
DBSALT000737
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
DTXSID7058757
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL821
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
m5867
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | Merck Index | ||
|
Guanidinium chloride
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
3YQC9ZY4YB
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
32735
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
100000077897
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY | |||
|
200-002-3
Created by
admin on Fri Dec 15 15:11:52 GMT 2023 , Edited by admin on Fri Dec 15 15:11:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
